Averna Therapeutics

Averna Therapeutics is a biotechnology company developing ribonucleic acid (RNA) and lipid nanoparticle (LNP)-based genomic medicines to durably and safely treat a broad range of diseases, including genetic diseases, cancer, and autoimmune conditions. Our proprietary technology is based on a natural system and inserts therapeutic genetic instructions into “safe harbor” sites in the genome – genomic regions that allow stable gene integration without disrupting normal cell function. Because our medicines are encoded in RNA, they can be delivered using validated, non-viral delivery platforms that are safe, efficient, scalable, and cost-effective, and that allow redosing to effect with a curative intent. Follow us on LinkedIn and stay in touch as we seek to advance develop RNA/LNP-based genomic medicines that deliver meaningful solutions for patients!